BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31093649)

  • 1. Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
    Brooks KM; Ibrahim ME; Castillo-Mancilla JR; MaWhinney S; Alexander K; Tilden S; Kerr BJ; Ellison L; McHugh C; Bushman LR; Kiser JJ; Hosek S; Huhn GD; Anderson PL
    J Antimicrob Chemother; 2019 Aug; 74(8):2352-2359. PubMed ID: 31093649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
    Brooks KM; Castillo-Mancilla JR; Blum J; Huntley R; MaWhinney S; Alexander K; Kerr BJ; Ellison L; Bushman LR; MacBrayne CE; Anderson PL; Kiser JJ
    J Antimicrob Chemother; 2019 Aug; 74(8):2360-2364. PubMed ID: 31081036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.
    Cerrone M; Alfarisi O; Neary M; Marzinke MA; Parsons TL; Owen A; Maartens G; Pozniak A; Flexner C; Boffito M
    J Antimicrob Chemother; 2019 Jun; 74(6):1670-1678. PubMed ID: 30815689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor.
    Ibrahim ME; Brooks KM; Castillo-Mancilla JR; McHugh C; Morrow M; Brothers J; MaWhinney S; Hosek S; Huhn G; Anderson PL
    AIDS Res Hum Retroviruses; 2018 Oct; 34(10):835-837. PubMed ID: 30047286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
    Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
    PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
    Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
    J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
    Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
    Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
    HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
    Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM
    J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
    Dickinson L; Yapa HM; Jackson A; Moyle G; Else L; Amara A; Khoo S; Back D; Karolia Z; Higgs C; Boffito M
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6080-6. PubMed ID: 26195515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
    Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
    Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
    Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
    Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers.
    Lu C; Jia Y; Chen L; Ding Y; Yang J; Chen M; Song Y; Sun X; Wen A
    J Clin Pharm Ther; 2013 Apr; 38(2):136-40. PubMed ID: 23278367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.